Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary - Primary - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary - Primary - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Preliminary - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Preliminary - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary - Primary - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-964251
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N9741
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - NCCTG-N0441
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-9741
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - GI - N0148
New strategies to improve drug development in carcinoid tumors (Alliance A021202) Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NETRF - - 2019 Abstract - No-Endpoint - Trial-Description-Only - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary - Primary - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NANETS - Pancreas - 2019 Abstract - Primary - Primary - GI - A021202
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , CALGB-89803
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - GI - C150705 , C89803 , C9581
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , C89803
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N9741
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Blanke, Charles D. , Bot, Brian M. , Thomas, David M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary - Primary - GI - NCCTG-924652
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Bonjer, H Jacob , Hop, Wim C J , Nelson, Heidi , Sargent, Daniel J ... - - Arch Surg - 2007 Manuscript - Secondary-not-in-original - Comprehensive - GI - NCCTG-1515
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Brown, Justin C , Zhang, Sui , Niedzwiecki, Donna , Saltz, Leonard B ... - - JNCI Cancer Spectr - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-89803
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) Brown, Justin C , Zhang, Sui , Ou, Fang-Shu , Venook, Alan P ... - - JNCI Cancer Spectr - 2019 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80405
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N0026 , NCCTG-N9741
Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741. Campbell, M. , Grothey, A. , Sargent, D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Primary - GI - N9741
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z6041
Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer Chan, Jennifer A. , Meyerhardt, Jeffrey A. , Niedzwiecki, Donna ... - - JAMA - 2008 Manuscript - Secondary-not-in-original - Primary - GI - C89803
Innovative estimation of survival using log-normal survival modelling on ACCENT database Chapman, J W , O'Callaghan, C J , Hu, N , Ding, K , Yothers, G A ... - - Br. J. Cancer - 2013 Manuscript - No-Endpoint - Primary - GI - N0441
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer Chen, Wei , Ghosh, Debashis , Raghunathan, Trivellore E. ... - - Biometrics - 2009 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-9741
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O’Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary - Primary - GI - N0441
Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials Chumsri, Saranya , Li, Zhou , Serie, Daniel J. ... - SABCS - Cancer Res - 2018 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N9831 , NSABP B-31
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N9831
Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial Civantos, Francisco J. , Zitsch, Robert P. , Schuller, David E. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - ACOSOG-Z0360
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001 Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z9001
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Corless, Christopher L. , Ballman, Karla V. , Antonescu, Cristina R. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary - Primary - GI - ACOSOG-Z9001
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Cushman, Stephanie M. , Jiang, Chen , Hatch, Ace J. , Shterev, Ivo ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary - Primary - GI - CALGB-80203
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) Das, R K , Furchtgott, L , Ou, F-S , Swanson, D , Hayete, B , Harms, B ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Das, Rahul K , Ou, Fang-Shu , Washburn, Cecilia , Nixon, Andrew B. ... - ESMO GI - Annals of Oncology - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - GI - N0441
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Ann. Surg. - 2013 Manuscript - Primary - Long-Term-Followup - GI - ACOSOG-Z9000
Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST) DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Lancet - 2009 Manuscript - Primary - Primary - GI - ACOSOG-Z9001
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary - Primary - GI - ACOSOG-Z9000
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007 Abstract - Primary - Primary - GI - ACOSOG-Z9001
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary - Primary - GI - N1048
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009 Manuscript - Primary - Primary - GI - N0144
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary - Primary - GI - N9741
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer Enzinger, P. C. , Burtness, B. , Hollis, D. R. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - CALGB-80403
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers Enzinger, Peter C. , Burtness, Barbara Ann , Niedzwiecki, Donna ... - - J. Clin. Oncol - 2016 Manuscript - Primary - Primary - GI - CALGB-80403 , ECOG-1206
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - - J. Clin. Oncol - 2018 Manuscript - Secondary - Primary - GI - CALGB-89803
Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-89803
Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study Farmer, Roger W. , McCall, Linda , Civantos, Francisco J. ... - - Otolaryngol Head Neck Surg - 2015 Manuscript - Secondary - Primary - GI - ACOSOG-Z0360
Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC) Federico Innocenti , Lenz, Heinz-Josef , Meyerhardt, Jeffrey ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer Fleshman, J. , Sargent, D. , Green, E. , Anvari, M. , Stryker, S. ... - - EJC Supplement - 2007 Abstract - Primary - Primary - GI - INT-0146
Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial Fleshman, J , Branda, ME , Sargent, DJ , Boller, AM , George, VV ... - - Ann. Surg. - 2019 Manuscript - Secondary - Primary - GI - ACOSOG-Z6051
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes Fleshman, James , Branda, Megan , Sargent, Daniel J. ... - - JAMA - 2015 Manuscript - Primary - Primary - GI - ACOSOG-Z6051
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Fleshman, James , Sargent, Daniel J , Green, Erin , Anvari, Mehran ... - - Ann. Surg. - 2007 Manuscript - Primary - Primary - GI - NCCTG-1515
Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. Foster, N. R. , Sinicrope, F. , Yothers, G. , Allegra, C. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - N994C
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841. Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. French, A. , Sinicrope, F. , Foster, N. , Thibodeau, S. , Sargent, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - GI - N994C
Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer French, Amy J. , Sargent, Daniel J. , Burgart, Lawrence J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary - Primary - GI - NCCTG-98-46-54
Dietary and lifestyle determinants of colon cancer recurrence and survival Fuchs, C. S. , Meyerhardt, J. A. , Ng, K. , Niedzwiecki, D. ... - NCI TSM - - 2008 Abstract - Secondary - Long-Term-Followup - GI - C89803
KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803 Fuchs, C. S. , Ogino, S. , Meyerhardt, J. A. , Irahara, N. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - GI - C89803
Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101 Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - CALGB-80101
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Fuchs, Charles S. , Goldberg, Richard M. , Sargent, Daniel J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary - Primary - GI - N9741
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) Fuchs, Charles S. , Niedzwiecki, Donna , Mamon, Harvey J. ... - - J. Clin. Oncol - 2017 Manuscript - Primary - Primary - GI - CALGB-80101
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) Fuchs, M. A. , Yuan, C. , Sato, K. , Niedzwiecki, D. , Ye, X. ... - - Ann. Oncol - 2017 Manuscript - Secondary - Primary - GI - CALGB-89803
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) Fuchs, Michael A. , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - PLoS ONE - 2014 Manuscript - Secondary - Primary - GI - CALGB-89803
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side. Furchtgott, Leon , Swanson, David , Hayete, Boris , Khalil, Iya ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial Garcia-Aguilar, J. , Shi, Q. , Thomas, C. R., Jr , Chan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z6041
Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study Garcia-Aguilar, Julio , Renfro, Lindsay A. , Chow, Oliver S. ... - - Lancet Oncol. - 2015 Manuscript - Secondary - Primary - GI - ACOSOG-Z6041
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012 Manuscript - Primary - Preliminary - GI - ACOSOG-Z6041
RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer Gbenedio, Oghenekevwe M. , Bonnans, Caroline , Grun, Delphine ... - - JCI Insight - 2019 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80203
Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). Gill, S. , Loprinzi, C. , Kennecke, H. , Grothey, A. , Nelson, G. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - GI - N0148
Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online Gill, Sharlene , Loprinzi, Charles , Kennecke, Hagen , Grothey, Axel ... - - Cancer - 2011 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - NCCTG-89-46-51 , NCCTG-914653
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Goel, Ajay , Nagasaka, Takeshi , Arnold, Christian N , Inoue, Toru ... - - Gastroenterology - 2007 Manuscript - Secondary - Primary - GI - CALGB-9865
A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in 9 first line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). Goldberg, R. M. , Kohne, C. H. , Seymour, M. T. , De Gramont, A. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Comprehensive - GI - N0545 , N9741
Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Goldberg, R. , Sargent, D. , Thibodeau, S. , Mahoney, M. , Shields, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - N0147
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Goldberg, Richard M , Sargent, Daniel J , Morton, Roscoe F ... - - J. Clin. Oncol. - 2004 Manuscript - Primary - Primary - GI - NCCTG-N9741
Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance) Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N1048
Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018 Abstract - Secondary - Primary - GI - CALGB-80803
Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance) Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017 Abstract - Primary - Preliminary - GI - CALGB-80803
Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984 Greenberg, J. A. , Shibata, D. , Herndon, J. E. 2nd ... - - Am Soc Colon Rectal Surg - 2008 Abstract - Primary - Long-Term-Followup - GI - C8984
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Greenberg, Jacob A , Shibata, David , Herndon, James E ... - - Dis. Colon Rectum - 2008 Manuscript - Primary - Long-Term-Followup - GI - C8984
New lesions vs. growth of existing disease: does it impact prognosis? Grothey, A. , Heun, J. M. , Branda, M. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N9741
Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - N054C
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary - Primary - GI - NCCTG-N9741
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer Grothey, A. , Sobrero, A.F. , Shields, A.F. , Yoshino, T. , Paul, J. ... - - N. Engl. J. Med. - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80702
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Grothey, Axel , Hedrick, Eric E , Mass, Robert D , Sarkar, Somnath ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original - Primary - GI - N9741
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary - Preliminary - GI - CALGB-80405
Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance) Guercio, Brendan J. , Zhang, Sui , Niedzwiecki, Donna , Li, Yanping ... - - PLoS ONE - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-89803
Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance) Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - Cancer Res - 2019 Abstract - Secondary - Primary - GI - CALGB-80405
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Guercio, Brendan J , Zhang, Sui , Ou, Fang-Shu , Venook, Alan P ... - - J. Clin. Oncol. - 2019 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80405
Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Primary - GI - NCCTG-N0349
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Haddock, Michael G , Swaminathan, Revathi , Foster, Nathan R ... - - J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - GI - N9942
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) Halfdanarson, Thorvardur R. , Foster, Nathan R. , Kim, George P. ... - - Oncologist - 2019 Manuscript - Primary - Primary - GI - N064B
A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary - Primary - GI - CALGB-89803
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance) Hatch, Ace J. , Ou, Fang-Shu , Zemla, Tyler , Liu , Star, Mark D. ... - ASCO GI - J. Clin. Oncol - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance). Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80203
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741 Heun, James M. , Grothey, Axel , Branda, Megan E. ... - - Oncologist - 2011 Manuscript - Secondary - Primary - GI - NCCTG-N9741
Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG). Hillman, SL , Sargent, DJ , Bot, BM , RP, DeMatteo , Perez, EA ... - ASCO - J Clin Oncol - 2007 Abstract - Secondary-not-in-original - Primary - GI - ACOSOG-Z9001
Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation Hillman, Shauna L. , An, Ming-Wen , O'Connell, Michael J. ... - - J Clin Oncol - 2009 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9741
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Shields, A. F. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - N0147
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011 Abstract - Primary - Primary - GI - N0147
Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-N0147
Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745 Hubbard, J. , Alberts, S. , Loui, W. , Mahoney, M. , Roberts, L. ... - - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - N0745
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance) Hubbard, Joleen M. , Mahoney, Michelle R. , Loui, William S. ... - - Target Oncol - 2017 Manuscript - Primary - Primary - GI - N0745
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary - Comprehensive - GI - ACCENT , CALGB-89803
Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance) Hurwitz, H. , Cushman, S. , Jiang, C. , Shterev, I. , Mahoney, M. R. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80203
The vitamin D receptor gene is a determinant of survival in advanced pancreatic cancer patients Innocenti, Federico , Owzar, Kouros , Jiang, Chen , Seiser, Eric ... - ECC - - 2015 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80303
Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance) Innocenti, Federico , Rashid, Naim , Mu, Wancen , Ou, Fang-Shu ... - ESMO - Annals of Oncology - 2019 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 Jackson, N. A. , Fuchs, C. S. , Niedzwiecki, D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - GI - C89803
Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - N064C
Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1 Jatoi, Aminah , Dakhil, Shaker R. , Foster, Nathan R. , Ma, Cynthia ... - - J Thorac Oncol - 2008 Manuscript - Primary - Primary - GI - N044B
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 Jatoi, Aminah , Green, Erin M. , Rowland, Jr. Kendrith M. ... - - Oncology - 2009 Manuscript - Secondary - Primary - GI - N0147
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Jatoi, Aminah , Martenson, James A , Foster, Nathan R ... - - Am. J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - GI - N0044
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. Jatoi, Aminah , Nguyen, Phuong L , Foster, Nathan , Sun, David ... - - J Support Oncol - 2007 Manuscript - Secondary - Primary - GI - N0242
Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors Jatoi, Aminah , Soori, Gamini , Foster, Nathan R. , Hiatt, Bradley ... - - J Thorac Oncol - 2010 Manuscript - Primary - Primary - GI - N044E
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Joensuu, Heikki , Eriksson, Mikael , Hall, Kirsten Sundby ... - - Cancer - 2014 Manuscript - Secondary-not-in-original - Comprehensive - GI - ACOSOG-Z9001
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008 Manuscript - Secondary - Preliminary - GI - N044E
Standardization and documentation of surgical and pathologic variables in a multi-institutional trial of adjuvant therapy for pancreatic cancer: Results from ACOSOG Z5031 Katz, M. H. , Merchant, N. B. , Brower, S. , Campbell, M. ... - SSO - SSO Annual Meeting - 2010 Abstract - Secondary-not-in-original - Primary - GI - ACOSOG-Z5031
Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial Katz, Matthew H. G. , Merchant, Nipun B. , Brower, Steven ... - - Ann. Surg. Oncol. - 2011 Manuscript - Secondary-not-in-original - Primary - GI - ACOSOG-Z05031
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew H. G. , Ou, Fang-Shu , Herman, Joseph M. ... - - BMC Cancer - 2017 Manuscript - No-Endpoint - Trial-Description-Only - GI - A021501
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Katz, Matthew H. G. , Shi, Qian , Ahmad, Syed A. , Herman, Joseph M. ... - - JAMA Surg - 2016 Manuscript - Primary - Primary - GI - A021101
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - GI - A021101
Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design Katz, Matthew HG , Marsh, Robert , Herman, Joseph M. , Shi, Qian ... - - Ann. Surg. Oncol. - 2013 Manuscript - No-Endpoint - Comprehensive - GI - A021101
Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew , Herman, Joseph M. , Ou, Fang-Shu , Marsh, Robert ... - ASCO - J. Clin. Oncol. - 2017 Abstract - No-Endpoint - Trial-Description-Only - GI - A021501
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). Kemeny, Nancy E , Niedzwiecki, Donna , Hollis, Donna R ... - - J. Clin. Oncol. - 2006 Manuscript - Primary - Primary - GI - CALGB-9481
North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - GI - N064A
Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma Kim, G. P. , Foster, N. R. , Salim, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - N064B
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary - Long-Term-Followup - GI - NCCTG-N0349
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Long-Term-Followup - GI - N0349
Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC) Kim, G. P. , Marsoni, S. , Monges, G. , Allegra, C. J. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - N994C
Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma Kim, G. P. , Oberg, A. L. , Foster, N. R. , Jaslowski, A. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - N034A
Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary - Primary - GI - NCCTG-N994C
Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841 Kim, George P. , Sargent, Daniel J. , Mahoney, Michelle R. ... - - J Clin Oncol - 2009 Manuscript - Primary - Primary - GI - N9841
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) Kindler, H. L. , Niedzwiecki, D. , Hollis, D. R. , Oraefo, E. A. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - CALGB-80303
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) Kindler, Hedy Lee , Niedzwiecki, Donna , Hollis, Donna ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - CALGB-80303
Randomized Phase II Study of Everolimus (E) versus Everolimus plus Bevacizumab (E+B) in Patients (Pts) with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance) Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. ... - NANETS - Pancreas - 2016 Abstract - Primary - Primary - GI - CALGB-80701
Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance) Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - GI - CALGB-80701
Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904 Kulke, Matthew H. , Tempero, Margaret A. , Niedzwiecki, Donna ... - - J Clin Oncol - 2009 Manuscript - Primary - Primary - GI - CALGB-89904
Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original - Primary - GI - N054C
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N054C
Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy Lafky, J. , Bot, B. , Morlan, B. ... - AACR - Proc Am Assoc Can Res - 2011 Abstract - Secondary-not-in-original - Primary - GI - N054C
Utilization of receptor targeted technetium Tc 99m Tilmanocept (lymphoseek injection) to identify and evaluate the pathological status of sentinel lymph nodes vs. elective neck dissection in patients with intraoral squamous cell carcinoma: A preliminary performance evaluation against technetium Tc 99m sulfur colloid in the ACOSOG-Z0360 study Lai, S. Y. , Agrawal, A. ... - SSO - Ann. Surg. Oncol. - 2013 Abstract - Secondary - Primary - GI - ACOSOG-Z0360
CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon Lenz, H. , Niedzwiecki, D. , Innocenti, F. , Blanke, C. , Mahoney, M. ... - ESMO - Ann. Oncol. - 2014 Abstract -
